Key result
LVAD unloading reverses metabolic and transcriptional defects in failing human myocardium.
Why the study?
Does mechanical unloading with an LVAD improve myocardial bioenergetics and metabolic gene expression in patients with advanced heart failure?
Does mechanical unloading with an LVAD improve myocardial bioenergetics and metabolic gene expression in patients with advanced heart failure?
Mechanical unloading with an LVAD reverses severe metabolic and transcriptional defects in the failing human heart, demonstrating significant metabolic resilience.
LVAD unloading may restore myocardial metabolism in advanced HF; extends mechanistic observations but remains hypothesis-generating pending larger studies.
BACKGROUND: Impaired bioenergetics is a prominent feature of the failing heart, but the underlying metabolic perturbations are poorly understood. METHODS AND RESULTS: We compared metabolomic, gene transcript, and protein data from 6 paired samples of failing human left ventricular tissue obtained during left ventricular assist device insertion (heart failure samples) and at heart transplant (post-left ventricular assist device samples). Nonfailing left ventricular wall samples procured from explanted hearts of patients with right heart failure served as novel comparison samples. Metabolomic analyses uncovered a distinct pattern in heart failure tissue: 2.6-fold increased pyruvate concentrations coupled with reduced Krebs cycle intermediates and short-chain acylcarnitines, suggesting a global reduction in substrate oxidation. These findings were associated with decreased transcript levels for enzymes that catalyze fatty acid oxidation and pyruvate metabolism and for key transcriptional regulators of mitochondrial metabolism and biogenesis, peroxisome proliferator-activated receptor γ coactivator 1α (PGC1A, 1.3-fold) and estrogen-related receptor α (ERRA, 1.2-fold) and γ (ERRG, 2.2-fold). Thus, parallel decreases in key transcription factors and their target metabolic enzyme genes can explain the decreases in associated metabolic intermediates. Mechanical support with left ventricular assist device improved all of these metabolic and transcriptional defects. CONCLUSIONS: These observations underscore an important pathophysiologic role for severely defective metabolism in heart failure, while the reversibility of these defects by left ventricular assist device suggests metabolic resilience of the human heart.
No takes yet. Share an insight, caveat, or question.
Gupte et al. (2014) studied Heart failure (n=18). Left ventricular assist device (LVAD) vs. Pre-LVAD failing left ventricular tissue and non-failing left ventricular tissue was evaluated on Myocardial metabolomic, gene transcript, and protein profiles. Mechanical unloading with a left ventricular assist device reversed metabolic and transcriptional defects in failing human myocardium, including restoring pyruvate metabolism and mitochondrial biogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: